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ABSTRACT  Many epidemiological studies show that genistein intake is effective for 
maintaining bone mineral density (BMD).  Because the reason for the efficacy of genistein as a 
bone protective agent in vivo remains unclear, we investigated the mechanisms underlying the 
effects of genistein on BMD in relation to BMP-Smad signaling systems.  When osteoblastic 
MC3T3-E1 cells were exposed to 1 µM genistein, they increased in number.  Combined 
administrations of 1 µM genistein and 1 µM of ICI 182,780 inhibited the increase in cell 
numbers.  Alkaline phosphatase (ALP) and Alizarin red staining showed high activities, 
indicating that genistein might promote estrogenic differentiation of MC3T3-E1 cells.  Moreover, 
ELISA determined that production of osteoprotegerin (OPG), which is expressed by osteoblasts, 
was higher when 1 µM genistein was added to the medium than in controls.  In contrast, 
when 10 ng/mL of noggin was administered in the medium, OPG production was inhibited. 
In order to clarify the underlying mechanism, we investigated the BMP-Smad signaling 
pathway.  When genistein was added to the medium, it induced gene expression of BMP-4. 
Immunofluorescence staining showed that genistein induced phosphorylation of Smad 1/5, a 
downstream molecule of BMP.  When noggin, which binds to BMP and blocks BMP signaling, 
was added to the medium, phosphorylation of Smad 1/5 was reduced.  These results indicate 
that genistein may regulate bone metabolism through the BMP-Smad signaling pathway as well 
as through the estrogen receptor pathway.
 (Accepted on October 29, 2012)
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INTRODUCTION
   Even after adolescence, bone is continuously 
destroyed and formed in order to maintain and 
repair itself and maintain body homeostasis１）, a 
process called bone remodeling.  Osteoclasts and 
osteoblasts are the main cells responsible for this 
process.  Osteoblasts exist in the surface of bone and 
are differentiated from mesenchymal stromal cells 
in response to bone morphogenetic protein (BMP), 
Runx2, and osterix２）.  MC3T3-E1 cells, derived 
from neonatal mouse calvariae, are well established 
as an in vitro model of osteoblast differentiation３）. 
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When various ligands bind to osteoblast receptors, 
osteoblasts produce proteins such as type I collagen, 
osteopontin, osteocalcin (OC), and alkaline 
phosphatase (ALP)４）.  These proteins can be used as 
differentiation markers of osteoblasts.  On the other 
hand, osteoclasts, which are differentiated from 
hematopoietic stem cells, are formed by cell surface 
contact with osteoblasts.  The receptor activator 
of the nuclear factor κB ligand (RANK ligand; 
RANKL) has been identified on the osteoblast 
surface; it binds to RANK on the cell surface of 
osteoclast precursors５）.  Cell-to-cell interaction 
between osteoblasts and osteoclast precursors is 
necessary to activate osteoclasts.  Osteoprotegerin 
(OPG), which is produced by osteoblasts, is an 
inhibitory factor in osteoclastogenesis that competes 
with RANK６）.  Together, these molecules regulate 
bone remodeling.
   Osteoporosis is one of major causes of fracture 
in postmenopausal women.  A decrease of estrogen 
level has been reported to accelerate bone loss７）. 
In order to minimize the effects of postmenopausal 
bone loss, it is necessary to achieve as high a bone 
mineral density (BMD) as possible in adolescence８）. 
Many epidemiological studies show that supplemental 
intake of various vitamins and phytoestrogens help 
maintain BMD９）.  Soy is a component of several 
traditional foods in Japan.  Regular intake of MK-7, 
a vitamin K2 analogue, in fermented soybeans (natto) 
contributes to the maintenance of bone health10）. 
Soybean isoflavones, which have a structural 
similarity to estrogen, also promote the maintenance 
of BMD11）.  Isoflavones consist mainly of genistein 
and daidzein, and the biological activity of genistein 
is higher than that of daidzein12，13）.
   When BMP-4 binds to receptors on the osteoblast 
surface, the downstream molecules Smad 1, 5, and 
8 are phosphorylated14）.  Phosphorylated Smads 
1/5/8 form heteromeric complexes with Smad 4, 
and these complexes are subsequently transported 
into the nucleus.  Thus, the BMP-4 signal expresses 
an osteoblast-specific physiological function15）. 
Noggin binds to BMP and is recognized as an 
inhibitor of BMP signaling16）.  The noggin/BMP 
interaction prevents BMPs from binding to their cell 
surface receptors, and disables the initiation of BMP 
signal transduction in target cells.
   In the present study, the effects of genistein on 
bone metabolism were investigated in relation to 
BMP-Smad signaling systems.
MATERIALS AND METHODS
Reagents
   Genistein and 17β-estradiol were obtained 
from Sigma-Aldrich Co. (St. Louis, MO, USA) 
and ICI 182,780, an estrogen receptor antagonist, 
was obtained from Tocris Cookson Ltd. (Bristol, 
UK).  They were dissolved in dimethyl sulfoxide 
(DMSO) to give a stock solution at 100 µM.  Fetal 
bovine serum (FBS) and Eagle’s Minimal Essential 
Medium α-modification (α-MEM) were obtained 
from Gibco Life Technologies Co., (Carlsbad, CA, 
USA).  α-MEM is free of phenol red which has an 
estrogen-like effect.  Bone morphogenetic protein 
(BMP) 4 and noggin were purchased from R&D 
Systems, Inc. (Minneapolis, MN, USA).  Anti-
phospho-Smad 1/5/8 antibody was purchased from 
Cell Signaling Technology Inc. (Beverly, MA, 
USA).  Osteoprotegerin (OPG) was measured using 
an enzyme-linked immunosorbent assay (ELISA) 
kit (RayBiotech, Inc., Norcross, GA, USA).  Other 
materials were commercial products of the highest 
grade available.
Cell culture
   Osteoblastic MC3T3-E1 cells derived from the 
calvaria of a newborn C57BL/6 mouse were obtained 
from the Riken Cell Bank and used in the 3rd to 5th 
passages.  The cells were maintained in α-MEM 
containing 10% (v/v) FBS.  All cells were plated at 
a density of 2.0 x 105 cells in 100-mm culture dishes 
at 37°C in a humidified atmosphere containing 5% 
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CO2.  When cells reached subconfluence, various 
concentrations of genistein (0.1 µM －100 µM) 
and/or ICI 182,780 (0.01 µM －10 µM) were added 
to the medium.  After 24 h and 96 h, the cells were 
counted. 
Estrogenic effect of genistein
   Subconfluent MC3T3-E1 cells were transiently 
transfected with reporter plasmids containing estrogen 
response element － chloramphenicol acetyl 
transferase (ERE–CAT)17）.  Transfected cells were 
co-cultured with the medium, 0.1 µM 17β-estradiol, 
1 µM genistein, and/or 1 µM ICI 182,780.
Measurement of alkaline phosphatase
   Alkaline phosphatase (ALP) is an early marker 
of osteoblast differentiation.  ALP activity was 
measured 12 h after administration of BMP-4 
and genistein.  ALP activity was measured after 
incubation at 37°C for 30 min with 6.7 mM 
p-nitrophenyl phosphate (Wako, Osaka, Japan) as 
the substrate in a buffer containing 0.1 M carbonate 
buffer (pH 9.8) and 2 mM MgCl2; the optical 
density was read at 405 nm.
Alizarin red S staining for measurement of 
mineralization 
   To assay mineralization, osteoblasts were cultured 
for 28 d.  Genistein (1 µM) was administered 
every three days.  On the third, 14th, and 28th day 
of culture, the cells were rinsed three times with 
phosphate buffered saline (PBS), with 90% ethanol, 
and then fixed in 70% ice-cold ethanol for 20 min at 
4°C.  The cells were stained with 1% Alizarin red S 
(Sigma-Aldrich) for 5 min at room temperature and 
washed five times with deionized water.  The stained 
cells were then dehydrated with 70% ethanol for 15 
min and counted manually using a microscope.
Quantification of various molecules using real-time PCR
   Total RNAs were prepared using an RNeasy 
Plus Mini kit (Qiagen, Tokyo, Japan).  First 
strand cDNA was synthesized from 5 µg of total 
RNA using a commercial Advantage RT-for-
PCR kit (Clontech Laboratories, Inc., Mountain 
View, CA, USA) according to the manufacturer’s 
instructions.  Real-time PCR was performed using 
the MX3000P (Stratagene, La Jolla, CA, USA). 
Thermocycling was performed in a final volume of 
20 µL containing 10 µL of Brilliant II Fast SYBR 
Green PCR Master Mix (Stratagene), 1 µL of 
cDNA, and 5 pmol/L of each primer.  To determine 
the number of copies of the targeted DNA in the 
samples, a relative standard curve (concentration-
threshold cycle) was generated by the dilution of 
cDNA from the calibrator.  Data were normalized 
to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) levels in the samples.  The primers 
used in the present study were BMP-4 (forward: 
5’ -AGGAGGAGGAGGAAGAGCAG-3’ , 
reverse: 5’-CACCTCATTCTCTGGGATGC-3’); 
osteocalcin (OC) (forward: 5’-TCTCTGCTCACT 
CTGCTGG-3’, reverse: 5’-GTGGTGCCATAG 
ATGCGCT-3’); ALP (forward: 5’-CGGGACTG 
GTACTCGGATAA-3’, reverse: 5’-ATTCCACG 
TCGGTTCTGTTC-3’); OPG (forward: 5’
-TGCAGAGAGTGTAGAGAGG-3’, reverse: 5’
-CAAGGTGTCTTGGTCTCCA-3’); GAPDH 
(forward:5’-TGTGTCCGTCGTGGATCTGA-3’, 
reverse:5’-CCTGCTTCACCACCTTCTTGA-3’). 
Gene expressions were examined at 2 and 24 h after 
genistein administration.
Osteoprotegerin measurement by ELISA
   MC3T3-E1 cells were seeded onto 100-mm 
diameter microplates at a density of 2.5 x 105/well 
and stimulated with 1 µM genistein with or without 
10 ng/mL noggin.  After 96 h, the production of 
osteoprotegerin (OPG) in the culture supernatant 
was measured using a commercially available 
mouse OPG ELISA kit (RayBiotech, Inc.).  
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Immunofluorescence staining for phospho-Smad 1/5 
nuclear translocation
   MC3T3-E1  cells were seeded onto glass 
coverslips at a density of 1.0 x 105 cells/well and 
incubated with genistein in the presence or absence 
of noggin for 48 h.  After 2 h incubation with 1 
µM genistein or 0.5 ng/mL BMP-4, the cells were 
fixed in chilled 4% paraform aldehyde (PFA) for 
10 min and washed with PBS.  Then, cells were 
incubated in blocking solution containing 2% goat 
serum, 3% BSA and 0.2% Tween 20 in PBS for 
30 min and with rabbit monoclonal anti-phospho-
Smad 1/5 antibody (#9516S, Cell Signaling, Tokyo, 
Japan) at 1:100 dilution in blocking buffer at 4°C 
overnight.  Cells were incubated with a 1:500 
dilution of secondary Alexa Fluor 594 goat anti-
rabbit IgG antibody (A-11037, Molecular Probes, 
Invitrogen) containing 1 µg/mL 4’6’-diamino-2-
phenylindole solution (DAPI, Dojindo, Kumamoto, 
Japan).  Finally, the coverslips were mounted using 
an antifade mounting medium containing DAPI (405 
nm) and photographed using a confocal microscope 
equipped  wi th  a  LD laser  (473nm:15mW, 
559nm:15mW) source of phase-contrast microscopy 
(Olympus, Tokyo, Japan).  Images were taken using 
an All-in-One Fluorescence Microscope BZ-8000 
(Keyence Japan, Osaka, Japan).
Statistical analysis
   All values were expressed as means ± standard 
deviation.  In order to compare the differences 
between control and administration groups, one-way 
ANOVA was employed using the JMP9 program 
(SAS Corp., Cary, NC, USA).
RESULTS
Confirmation of estrogenic effect of genistein
   In order to identify the estrogenic effect of 
genistein, activation of estrogen response element 
(ERE)-containing genes was measured by means 
of a chloramphenicol acetyl transferase (CAT) 
reporter construct with an upstream ERE site in 
MC3T3-E1 cells.  The CAT assay suggested that 
1 µM genistein activated transcription through 
binding with estrogen receptors, although its 
activity was approximately 38.8% of 17β-estradiol 
(Fig. 1).  Moreover, 1 µM ICI 182,780 had slightly 
lower CAT activity than 1 µM genistein, although 
the difference was not statistically significant.  This 
result indicated that genistein bound to estrogen 
receptors and might have an estrogenic effect.
Effect of genistein on cell proliferation
   Changes in cell number were investigated 24 
and 96 h after administration of concentrations of 
0.1 or 1 µM genistein with or without ICI 182,780 
(Fig. 2A, B).  MC3T3-E1 cells (2.0 x 105) were 
seeded in 100-mm culture dishes.  No statistical 
difference was observed between control and 
genistein-administered cells 24 h after genistein 
administration.  On the other hand, the MC3T3-E1 
cells cultured with 0.1 or 1 µM genistein with 0.1 
µM ICI 182,780 showed a significant decrease 
in cell number at 24 h compared with those 
without ICI 182,780.  Significant increases of cell 
numbers were observed at 96 h after 0.1 or 1 µM 
genistein administration.  Moreover, combined 
administrations of genistein and ICI 182,780 
significantly decreased cell numbers compared with 
Fig. 1.　Estrogenic effect of genistein.  A CAT assay 
suggested that 1 µM genistein activated transcription through 
binding with estrogen receptors, although its activity was 
about 40% of 17β -estradiol. *: p<0.05
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genistein administration alone.
Osteogenic effect of genistein
   In order to investigate the osteogenic effect of 
genistein, alkaline phosphatase (ALP) activity 
and alizarin red staining were examined.  Twelve 
hours after 0.3 ng/mL BMP-4s was administered, 
approximately 0.55 mmol/L of ALP activity had 
been induced.  On the other hand, 3 ng/mL BMP-
4s did not induce ALP activity, while 1 ng/mL 
BMP-4s induced approximately 0.25 mmol/L ALP 
activity (Fig. 3A).  These results indicated that a 
(A) (B)
Fig. 2.　Effect of genistein on osteoblast proliferation.  Changes in cell numbers were investigated at 24 h (A) and 96 h (B) after 
administration of genistein and/or ICI 182,780.  *: p<0.05, **: p<0.01  (B) **: p<0.01.  a: Differences between control and 0.1 
µM genistein, control and 1 µM genistein, control and 1 µM genistein +1 µM ICI 182,780, control and 0.1 µM genistein +0.1 
µM ICI 182,780, and control and 1 µM genistein +0.1 µM ICI 182,780. b: Differences between 0.1 µM genistein and 0.1 µM 
genistein +1 µM ICI 182,780, 0.1 µM genistein and 1 µM genistein +0.1 µM ICI 182,780. c: Differences between 1 µM genistein 
and 0.1 µM genistein +1 µM ICI 182,780, 1 µM genistein and 1 µM genistein +0.1 µM ICI 182,780, and 1 µM genistein and 
0.1 µM genistein +0.1 µM ICI 182,780. *: p<0.05 d: Differences between control and 0.1 µM genistein +1 µM ICI 182,780. e: 
Differences between 0.1 µM genistein and 0.1 µM genistein +0.1 µM ICI 182,780, and 0.1 µM genistein and 1 µM genistein +1 
µM ICI 182,780. f: Differences between 1 µM genistein and 1 µM genistein +1 µM ICI 182,780.
Fig. 3.　Effect of genistein on estrogenic activity.  (A) ALP activity as a differentiation marker was measured 12 h after 
administration of genistein.  Significant differences were observed between control and 0.3 ng/mL BMP-4, control and 1 ng/
mL BMP-4, control and 1 µM genistein, 0.3 ng/mL BMP-4 and 1 ng/mL BMP-4, and 0.3 ng/mL BMP-4 and 1 µM genistein.**: 
p<0.01  (B) Alizarin red staining showed that genistein induced osteoblastic calcification compared with control at 28 d.  Areas of 
calcification were calculated as mm2; control: 1.9±0.3, 1 µM genistein: 18.9±11.8, 1 µM genistein +1 µM ICI 182,780: 4.4±3.0, 
and 17β -estradiol: 5.7±3.6. *: p<0.05
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low concentration of BMP-4 might induce cell 
differentiation, and 1 µM genistein induced ALP 
activity as high as 1 ng/mL BMP-4.
   Because we did not add a differentiation factor 
to the medium, a long incubation period (28 d) 
was needed to observe the bone mineralization 
process using Alizarin red staining.  Treatment 
with 1 µM genistein significantly enlarged the 
area of calcification in MC3T3-E1 cells compared 
with the control (Fig. 3B).  Administration of 1 
µM ICI 182,780 with genistein showed a tendency 
to decrease the area of calcification (p<0.10).  In 
contrast, administration of 1 µM 17β-estradiol 
did not produce a significant difference from the 
control.  These findings implied-the genistein might 
induce the calcification of osteoblasts through an 
estrogen receptor-dependent pathway. 
Induction of osteoblast-specific genes by genistein 
   Because genistein may induce both cel l 
proliferation and cell differentiation, expressions 
of osteoblast-specific genes were examined. 
Expression of each gene was adjusted to the 
GAPDH control.  When mRNA expression of 
the control was taken as 1.0, the relative mRNA 
expressions of BMP-4, ALP, OPG, and OC were 
1.34, 1.08, 5.40, and 1.56, respectively, when 
MC3T3-E1 cells were cultured with 1 µM genistein 
for two hours (Fig. 4, left panel).  In addition, the 
relative mRNA expressions-at 24 h were 0.76, 1.09, 
0.58, and 0.76, respectively.  If changes of relative 
mRNA expressions between 0.5 to 2.0 times were 
not significant, genistein only enhanced OPG 
mRNA expression in early cultures.
Induction of osteoprotegerin by genistein
   It is assumed that genistein induced proliferation 
and differentiation of osteoblasts both through 
estrogen-receptor and BMP-Smad signaling 
pathways.  Because genistein induced only OPG 
mRNA expression among several genes related to 
osteogenesis, the production of OPG was measured 
using ELISA in MC3T3-E1 cells with or without 
noggin (a BMP inhibitor).  As shown in Fig. 5, 
MC3T3-E1 cells secreted 2513.0±101.0 pg/mL 
OPG, and this was significantly higher than that of 
control (without genistein, 1607.7±63.6 pg/mL). 
Moreover, the addition of 10 ng/mL of noggin with 
Fig. 4.　Relative expression of osteoblast-specific molecules after administration of 1 µM genistein.  mRNA expression was 
adjusted to GAPDH as a control.  mRNA expression of control is indicated as 1.0.
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Fig. 5.　Measurement of OPG production by ELISA.  MC3T3-E1 cells were cultured for 96 h with 1 µM genistein with or 
without 10 ng/mL noggin.  Culture supernatants were obtained, and osteoprotegerin (OPG) productionwas measured using an 
ELISA kit.  **: p<0.01, *: p<0.05
genistein to the MC3T3-E1 cell culture significantly 
decreased OPG production of MC3T3-E1 cells 
(1486.3±88.1 pg/mL), compared with that of 
OPG production due to genistein alone, and the 
production capacity returned to the control level. 
Thus, the OPG production of MC3T3-E1 cells 
induced by genistein might be transduced through 
the activation of BMP-Smad signaling pathways.  
Genistein activates BMP-Smad signaling in 
MC3T3-E1 cells
   Since genistein tended to induce BMP-4 mRNA 
expression and combined administration of 
genistein and noggin inhibited the production 
of OPG, the BMP-Smad signaling pathway 
was invest igated.   Nuclear  local izat ion of 
phosphorylated Smad (pSmad) 1/5 was measured 
using immunofluorescence staining in MC3T3-
E1 cells cultured with BMP-4 and genistein with 
or without noggin.   The number of pSmad 1/5-
positive cells was higher in the BMP-4 or genistein-
treated cells than in the control. (Fig. 6A-C).  On the 
other hand, pretreatment with noggin significantly 
reduced the number of pSmad 1/5-positive cells in 
the BMP-4, and genistein-treated cells (Fig. 6E, F). 
The pSmad-positive index of genistein-administered 
cells was 4.9 times higher than that of the control 
(Fig. 6G), and the pSmad-positive index of BMP-
4-administered cells was 3.6 times higher than that 
of the control.  Furthermore, the index induced by 
genistein was higher than that induced by BMP-4. 
In addition, when noggin was administered with 
genistein, the pSmad-positive index was reduced 
compared with when genistein was administered 
alone.  These results indicate that genistein may 
affect the BMP-Smad signaling pathway directly. 
The administration of noggin to the MC3T3-E1 
cells cultured with BMP-4 did not affect the pSmad-
positive index, although noggin decreased the index 
in genistein-supplemented cultures.  The reason why 
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noggin did not inhibit BMP-4 induced Smad 1/5 
phosphorylation in this culture system was not clear; 
the exogenous BMP may have been too strong to be 
suppressed by noggin administration because this 
activation was intrinsic enough not to be suppressed 
by noggin.
DISCUSSION
   Isoflavones occur naturally as glycosidic forms 
and need to be hydrolyzed to form isoflavone 
aglycones18）.  Many epidemiological studies show 
that dietary supplementation with isoflavone 
aglycones is effective to prevent bone mineral 
loss19）.  This effect occurs because isoflavones 
have a structural similarity to estrogen and act as 
agonists of estrogen18）.  Among various isoflavone 
aglycones, genistein has the highest physiological 
activity.  In the present study, we investigated 
the effect of genistein on induction of osteoblast 
differentiation and production of OPG in MC3T3-
E1 cells through not only the estrogen receptor-
dependent pathway but also the BMP-Smad 
signaling pathway.  Baicalin, one of the flavonoids, 
induces osteoblast differentiation through the Wnt/
β-catenin signaling pathway20）.  Park reported 
that melatonin promoted osteoblast differentiation 
through BMP/Wnt signaling21）.  These findings 
suggest that the Wnt signaling pathway is essential 
for osteoblast differentiation.  On the other hand, the 
Wnt signaling pathway modulates differentiation, 
Fig. 6.　Nuclear localization of pSmad 1/5 by immunofluorescence staining.  Nuclear localization of pSmad 1/5 is indicated 
by red.  MC3T3-E1 cells were cultured without noggin (A-C) and with 10 ng/mL noggin (D-F).  The pSmad-positive indexes 
calculated as (the number of pSmad 1/5-positive cells/number of total cells) were A: 19.4±5.4, B: 67.4±14.4, C: 94.2±3.7, D: 
12.2±2.1, E: 56.7±9.2, F: 43.7±11.6 (G).  **: p<0.01, *: p<0.05
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proliferation, and mineralization in bone formation 
as a downstream of BMPs22，23）.  Because the Wnt 
signaling and BMP-Smad signaling pathways are 
closely related to each other, we investigated the 
effects of genistein on the BMP-Smad signaling 
pathway.  
   In the present study, we confirmed that genistein 
induced pSmad 1/5 and that noggin reduced this 
induction, although noggin itself did not affect 
phosphorylation.  Even though we did not confirm 
that genistein affected the Wnt signaling pathway 
and bound to BMP receptors directly, our results 
indicate that genistein might affect BMP signaling. 
Moreover, genistein induced ALP activity, indicating 
that genistein might induce cell differentiation. 
On the other hand, when genistein was added to 
the medium, the number of cells was significantly 
increased, and ICI 182,780 partially blocked this 
increment.  The CAT assay revealed that genistein 
may bind to estrogen receptors and may have 
an estrogenic effect.  These results indicate that 
genistein may affect not only cell proliferation due 
to stimulation of the estrogen receptor-dependent 
pathway but also cell differentiation by the BMP-
Smad signaling pathway.   
   Osteoclasts are derived from hematopoietic 
stem cells and are differentiated by cell-to-cell 
contact with osteoblasts24）.  One possible strategy 
to prevent osteoporosis is reduction of osteoclast 
function.  OPG is produced by osteoblasts and 
inhibits osteoclast differentiation acting as a decoy 
receptor of RANKL24）.  The present study revealed 
that genistein affected OPG production, and that 
this effect was inhibited by noggin.  These findings 
may indicate that genistein might affect cell 
differentiation by the BMP-Smad signaling pathway. 
Although the affinity of genistein to estrogen 
receptors is about 1/1,000 that of 17β-estradiol25）, 
production of OPG might prevent BMD loss. 
Moreover, treatment with glucocorticoids results in 
a substantial loss of bone, whereas glucocorticoids 
inhibit OPG mRNA expression26）.  Genistein acts 
as a tyrosine kinase inhibitor, and administration of 
genistein also succeeds in preventing glucocorticoid-
induced osteoporosis27）.  These findings indicate that 
genistein might maintain BMD through production 
of OPG.
   Bone metastasis is observed in some cancers, 
and the OPG/RANK/RANKL system plays an 
important role in this process28）.  It has been 
reported that 35% of patients with prostate cancer 
develops hematogenous metastases, of which bone 
metastasis is the most frequent28）.  OPG inhibits the 
formation of RANK/RANKL interaction, so that 
OPG might prevent metastatic bone destruction in 
prostate cancer.   On the other hand, genistein in 
combination with lower doses of docetaxel might 
enhance the antitumor and antimetastatic activities 
of docetaxel, while reducing the side effects of 
docetaxel.  Moreover, genistein itself down-
regulates some genes critical to the promotion of 
cell cycle progression and cell proliferation, and 
up-regulated some genes related to the induction of 
apoptosis and cell cycle arrest29，30）.  Taken together, 
genistein might act not only as an antitumor agent 
but also reduce the side effects of docetaxel.  
   In Japan, although the intake calcium from 
foods is much lower than in Western countries, 
the prevalence of osteoporosis is much lower31）. 
Moreover, it has been suggested that consumption of 
soy foods may contribute to the relatively low rates 
of breast, colon, and prostate cancers in Japan32）. 
Genistein possesses weak estrogenic activity, and is 
also a specific inhibitor of protein tyrosine kinases; 
it also inhibits DNA topoisomerases and other 
critical enzymes involved in signal transduction. 
These effects of genistein might promote anticancer 
effects.  Soy consumption in Japan is much higher 
than in Western countries32）, and may contribute to 
the lower rates of osteoporosis and cancers.  
   This study has some limitations.  First, we 
did not investigate the Wnt signaling pathway, 
30 Kawasaki Medical Journal
which may affect bone mineral metabolism.  The 
relationship between the Wnt-signaling and BMP-
Smad signaling pathways should be investigated. 
Second, although genistein affected not only 
cell proliferation but also cell differentiation, the 
timing of this switch was not investigated. Further 
studies should be performed in order to clarify this 
switching system.
   In conclusion, genistein may induce osteoblast 
proliferation and differentiation through the BMP-
Smad signaling pathway as well as the estrogen 
receptor-dependent pathway.  These results suggest 
that genistein is effective to maintain bone mineral 
density.
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